Research › Fact Sheets › IDXX

IDEXX LABORATORIES INC /DE

LISTEDNASDAQ

SYMBOLIDXX

SIC2835

STATE OF INC.DE

FISCAL YEAR ENDSDecember 31

CIK874716

IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · LARGE ACCELERATED FILER · 10 FISCAL YEARS OF SEC XBRL DATA, 2016–2025

Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.

CAPITALIZATION 12/31/25

($ millions)	Amount	%
Total debt	450	21.9
Stockholders' equity	1,605	78.1
Total capitalization	2,055	100.0

78,781,116 shares outstanding at 31 July 2026 (cover page of the 10-Q filed 4 August 2026).

LONG-TERM DEBT 12/31/25

($ millions)	Amount
Long-term debt, incl. current maturities	450
Long-term debt, noncurrent	375
Current maturities	75

CAPITAL STOCK 12/31/25

Common shares authorized	120,000,000
Common shares issued	108,369,000
Treasury shares	28,657,000
Par or stated value per share ($)	0.1
Outstanding at 7/31/26	78,781,116

DIVIDENDS DECLARED/PAID

Fiscal year	Per share $	Payout %
2025	–	–
2024	–	–
2023	–	–
2022	–	–
2021	–	–

HISTORY AND BUSINESS

HISTORY: Incorporated in Delaware.

BUSINESS: Classified by the SEC under Standard Industrial Classification 2835, In Vitro & In Vivo Diagnostic Substances. Large accelerated filer. Principal executive office: One Idexx Drive, Westbrook, ME 04092-2041. Fiscal year ends December 31. For a description of the business, see Item 1 of the latest 10-K.

CONSOLIDATED INCOME ACCOUNT, YEARS ENDED

($ millions)	12/31/25	12/31/24	12/31/23
Revenues	4,304	3,898	3,661
Cost of revenues	1,644	1,519	1,471
Gross profit	2,660	2,379	2,190
Research and development	251	220	191
Depreciation and amortization	145	130	115
Operating income	1,360	1,128	1,097
Interest expense	39	31	42
Income before income taxes	1,324	1,110	1,061
Income taxes	265	222	216
Net income	1,059	888	845
Earned per share, diluted ($)	13.08	10.67	10.06
Dividends per share ($)	–	–	–

CONSOLIDATED BALANCE SHEET

($ millions)	12/31/25	12/31/24
Cash and equivalents	180	288
Receivables, net	552	474
Inventories	378	382
Total current assets	1,414	1,400
Property, plant and equipment, net	747	713
Goodwill	414	405
Total assets	3,351	3,293
Total current liabilities	1,149	1,068
Long-term debt	375	450
Total liabilities	1,745	1,698
Stockholders' equity	1,605	1,595
Total liabilities and equity	3,351	3,293

TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)

Fiscal year ended	Revenues	Oper. income	Net income	Net margin %	EPS diluted $	Div. per share $	Oper. cash flow	Capital expend.	Free cash flow	Total assets	Total liabilities	Total debt	Stockholders' equity	ROE %	Debt / equity
12/31/25	4,304	1,360	1,059	24.6	13.08	–	1,182	125	1,057	3,351	1,745	450	1,605	66.0	0.28
12/31/24	3,898	1,128	888	22.8	10.67	–	929	121	808	3,293	1,698	618	1,595	55.7	0.39
12/31/23	3,661	1,097	845	23.1	10.06	–	907	134	773	3,260	1,775	698	1,485	56.9	0.47
12/31/22	3,367	899	679	20.2	8.03	–	543	149	394	2,747	2,138	770	609	111.6	1.26
12/31/21	3,215	932	745	23.2	8.60	–	756	120	636	2,437	1,747	851	690	107.9	1.23
12/31/20	2,707	695	582	21.5	6.71	–	648	107	541	2,295	1,662	909	632	92.0	1.44
12/31/19	2,407	553	428	17.8	4.89	–	459	155	304	1,832	1,655	699	177	241.0	3.94
12/31/18	2,213	491	377	17.0	4.26	–	400	116	284	1,537	1,547	602	(10)	-3963.3	-63.26
12/31/17	1,969	413	263	13.4	2.94	–	373	74	299	1,713	1,767	607	(54)	-486.3	-11.21
12/31/16	1,775	350	222	12.5	2.44	–	339	65	274	1,531	1,639	594	(108)	-204.9	-5.48

Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.

REGISTRANT:

IDEXX LABORATORIES INC /DE
CIK 874716 · EIN 01-0393723

PRINCIPAL OFFICE:

One Idexx Drive, Westbrook, ME 04092-2041
Tel.: 2075560300

INCORPORATED:

Delaware

INDUSTRY (SEC SIC CODE):

2835 · In Vitro & In Vivo Diagnostic Substances

FILER STATUS:

Large accelerated filer

LATEST ANNUAL REPORT:

10-K for period ended 12/31/25, filed 20 February 2026

RECENT FILINGS (ANNUAL REPORT REFERENCES BELOW):

8/4/26	10-Q	period 6/30/26
8/4/26	8-K	period 8/4/26
5/15/26	8-K	period 5/12/26
5/5/26	10-Q	period 3/31/26
5/5/26	8-K	period 5/5/26
3/27/26	DEF 14A	period 12/31/25
3/26/26	8-K	period 3/24/26
2/20/26	10-K	period 12/31/25

Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/20/26) · 10-K FY2024 (filed 2/21/25) · 10-K FY2023 (filed 2/22/24) · 10-K FY2022 (filed 2/16/23) · 10-K FY2021 (filed 2/16/22) · 10-K FY2020 (filed 2/12/21) · 10-K FY2019 (filed 2/14/20) · 10-K FY2018 (filed 2/15/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.